Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer

Overview

The purpose of this study is to determine proportion of patients presented a search allelic imbalance of expression of genes BRCA 1 and 2 in population with hereditary breast and/or ovarian cancer risk and negative for deletion mutation BRCA 1 and 2 genes

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2012

Interventions

  • Genetic: blood collection
    • blood collection for research quantification of allelic expression in the gene BRCA1.
  • Genetic: blood collection
    • blood collection for research quantification of allelic expression in the gene BRCA1.

Arms, Groups and Cohorts

  • Experimental: patients group
    • Patients with ovarian and/or breast cancer
  • Other: control population
    • control population without history of breast and/or ovarian cancer

Clinical Trial Outcome Measures

Primary Measures

  • estimate the proportion of patients with allelic imbalance at the level of expression of BRCA1
    • Time Frame: blood sample at baseline, no follow-up in this study
    • The main objective of this study is to estimate the proportion of patients with allelic imbalance at the level of expression of BRCA1 in a population meeting the criteria suggestive of a hereditary predisposition to breast and / or ovarian cancer , and negative for deleterious mutations of BRCA 1 and BRCA 2.

Secondary Measures

  • Study the variability of the measurement of the allelic expression depending on the position of SNPs
    • Time Frame: blood sample at baseline, no follow-up in this study
    • Study the variability of the measurement of the allelic expression depending on the position of SNPs (Single Nucleotide Polymorphism) in the gene, in order to extend this research to variants of unknown significance whatever their position in the gene.
  • proportion of patients with allelic imbalance at the level of expression of the BRCA2 gene
    • Time Frame: blood sample at baseline, no follow-up in this study
    • Estimate the proportion of patients with allelic imbalance at the level of expression of the BRCA2 gene in the same population.
  • Observe the possible effect of age
    • Time Frame: blood sample at baseline, no follow-up in this study
    • The frequency of allelic imbalance of expression will be compared depending on the age of the witnesses in the control population. The potential effect of age on the presence or absence of allelic imbalance of expression will be observed.

Participating in This Clinical Trial

Inclusion Criteria

For patients

  • Women with breast cancer and / or ovarian cancer meet criteria suggestive of a hereditary predisposition – Deleterious mutation of BRCA1 and BRCA2 sought and not highlighted – Age ≥ 18 years – Agreeing to participate in the study (a collection of signed informed consent) For control population – Women with no history of breast and / or ovarian cancer and no family history of breast and / or ovarian cancer among family members on the 1st and 2nd degree before age 50 for breast cancer and before 60 years for ovarian cancer – Agreeing to participate in the study (a collection of signed informed consent) Exclusion Criteria:

For patients:

  • Patients with a known deleterious mutation in BRCA1 and BRCA2 – Patients do not meet criteria suggestive of a hereditary predisposition – Persons deprived of liberty or under guardianship (including guardianship) For control population: – Males – Personal or family history of breast and / or ovarian cancer (breast or ovarian cancer in their family experienced 1st and 2nd degree before age 50 for breast cancer before age 60 for cancer ovarian) – Persons deprived of liberty or under guardianship (including guardianship)

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Centre Francois Baclesse
  • Provider of Information About this Clinical Study
    • Dr Agnès HARDOUIN, Centre François BACLESSE
  • Overall Official(s)
    • Agnès HARDOUIN, MD, Principal Investigator, Centre François Baclesse

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.